BI
Therapeutic Areas
Kodiak Sciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Tarcocimab Tedromer (KSI-301) | Diabetic Retinopathy / Non-Proliferative Diabetic Retinopathy (without DME) | Phase 3 |
| KSI-501 | Retinal Vascular Diseases (wAMD, DME) | Phase 1 |
| KSI-101 | Macular Edema Secondary to Inflammation (MESI) | Phase 1b |
Leadership Team at Kodiak Sciences
VP
Victor Perlroth
Chairman and Chief Executive Officer
JB
John Borgeson
Chief Financial Officer
DS
Dolly S. Chang
Chief Scientific Officer
AQ
Almas Qudrat
Chief Quality Officer
PV
Pablo Velazquez-Martin
Chief Medical Officer
LD
Laurent Ducry
Senior Vice President, Biologics Development and Manufacturing
HL
Hong Liang
Senior Vice President, Development
SR
Stephen Raillard
Senior Vice President, Chemical Development and Manufacturing
GC
Gorton Chiu
Vice President, Finance
RA
Robert A. Profusek
Partner and Global Chair M&A, Jones Day (Board Member)